Search

Your search keyword '"Lambert, John M."' showing total 297 results
Start Over Author "Lambert, John M."
297 results on '"Lambert, John M."'

6. The Lake Effect: Lake Michigan, Landscape Evolution, and the Archaeological Record of the Chicago Region.

Author

Tolmie, Clare and Lambert, John M.

Subjects
*SHORELINES, *SAND dunes, *LAKES, *LAKE sediments, *VEGETATION patterns, *LANDSCAPE archaeology, *CULTURAL landscapes
Abstract

Lake Michigan continues to have a major impact on the environment in the Chicago region, and changes in lake levels were a major driver of landscape evolution throughout the late Pleistocene and Holocene. Fluctuating lake levels reduced or increased the extent and character of terrestrial resources. The landscape has also been altered by erosional and aggradational processes from near-shore currents and wave action. Interpretation of archaeological site and settlement patterns in this region requires an understanding of the factors that have shaped and continue to shape this landscape. In the PaleoIndigenous and Archaic periods, foraging groups adapted to rapidly changing vegetation patterns and episodes of lake transgression and recession that opened or closed new habitats. In the Woodland and Upper Mississippian periods, lake levels stabilized, but the landscape continued to evolve, with erosion and deposition of sediments along Lake Michigan shorelines. Evidence for lake-level fluctuations over the last 12,000 years is available from a variety of data sets, including those for deep lacustrine sediments, ostracods, abandoned shorelines, and sand dunes. By synthesizing these data and utilizing GIS to reconstruct past lakeshores, we seek to better understand how people interacted with and adjusted to this dynamic landscape. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Data from IMGN853, a Folate Receptor-α (FRα)–Targeting Antibody–Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors

Author

Ab, Olga, primary, Whiteman, Kathleen R., primary, Bartle, Laura M., primary, Sun, Xiuxia, primary, Singh, Rajeeva, primary, Tavares, Daniel, primary, LaBelle, Alyssa, primary, Payne, Gillian, primary, Lutz, Robert J., primary, Pinkas, Jan, primary, Goldmacher, Victor S., primary, Chittenden, Thomas, primary, and Lambert, John M., primary

Published
2023
Full Text
View/download PDF

9. Table S2 from A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity

Author

Miller, Michael L., primary, Fishkin, Nathan E., primary, Li, Wei, primary, Whiteman, Kathleen R., primary, Kovtun, Yelena, primary, Reid, Emily E., primary, Archer, Katie E., primary, Maloney, Erin K., primary, Audette, Charlene A., primary, Mayo, Michele F., primary, Wilhelm, Alan, primary, Modafferi, Holly A., primary, Singh, Rajeeva, primary, Pinkas, Jan, primary, Goldmacher, Victor, primary, Lambert, John M., primary, and Chari, Ravi V.J., primary

Published
2023
Full Text
View/download PDF

10. Supplementary figures 1 through 9, supplementary tables 1 through 6, and supplementary materials from IMGN853, a Folate Receptor-α (FRα)–Targeting Antibody–Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors

Author

Ab, Olga, primary, Whiteman, Kathleen R., primary, Bartle, Laura M., primary, Sun, Xiuxia, primary, Singh, Rajeeva, primary, Tavares, Daniel, primary, LaBelle, Alyssa, primary, Payne, Gillian, primary, Lutz, Robert J., primary, Pinkas, Jan, primary, Goldmacher, Victor S., primary, Chittenden, Thomas, primary, and Lambert, John M., primary

Published
2023
Full Text
View/download PDF

11. Supplementary Methods from A New Triglycyl Peptide Linker for Antibody–Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells

Author

Singh, Rajeeva, primary, Setiady, Yulius Y., primary, Ponte, Jose, primary, Kovtun, Yelena V., primary, Lai, Katharine C., primary, Hong, E. Erica, primary, Fishkin, Nathan, primary, Dong, Ling, primary, Jones, Gregory E., primary, Coccia, Jennifer A., primary, Lanieri, Leanne, primary, Veale, Karen, primary, Costoplus, Juliet A., primary, Skaletskaya, Anna, primary, Gabriel, Rabih, primary, Salomon, Paulin, primary, Wu, Rui, primary, Qiu, Qifeng, primary, Erickson, Hans K., primary, Lambert, John M., primary, Chari, Ravi V.J., primary, and Widdison, Wayne C., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figures S1-S5 from A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity

Author

Miller, Michael L., primary, Fishkin, Nathan E., primary, Li, Wei, primary, Whiteman, Kathleen R., primary, Kovtun, Yelena, primary, Reid, Emily E., primary, Archer, Katie E., primary, Maloney, Erin K., primary, Audette, Charlene A., primary, Mayo, Michele F., primary, Wilhelm, Alan, primary, Modafferi, Holly A., primary, Singh, Rajeeva, primary, Pinkas, Jan, primary, Goldmacher, Victor, primary, Lambert, John M., primary, and Chari, Ravi V.J., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figures from A New Triglycyl Peptide Linker for Antibody–Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells

Author

Singh, Rajeeva, primary, Setiady, Yulius Y., primary, Ponte, Jose, primary, Kovtun, Yelena V., primary, Lai, Katharine C., primary, Hong, E. Erica, primary, Fishkin, Nathan, primary, Dong, Ling, primary, Jones, Gregory E., primary, Coccia, Jennifer A., primary, Lanieri, Leanne, primary, Veale, Karen, primary, Costoplus, Juliet A., primary, Skaletskaya, Anna, primary, Gabriel, Rabih, primary, Salomon, Paulin, primary, Wu, Rui, primary, Qiu, Qifeng, primary, Erickson, Hans K., primary, Lambert, John M., primary, Chari, Ravi V.J., primary, and Widdison, Wayne C., primary

Published
2023
Full Text
View/download PDF

14. Data from A New Triglycyl Peptide Linker for Antibody–Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells

Author

Singh, Rajeeva, primary, Setiady, Yulius Y., primary, Ponte, Jose, primary, Kovtun, Yelena V., primary, Lai, Katharine C., primary, Hong, E. Erica, primary, Fishkin, Nathan, primary, Dong, Ling, primary, Jones, Gregory E., primary, Coccia, Jennifer A., primary, Lanieri, Leanne, primary, Veale, Karen, primary, Costoplus, Juliet A., primary, Skaletskaya, Anna, primary, Gabriel, Rabih, primary, Salomon, Paulin, primary, Wu, Rui, primary, Qiu, Qifeng, primary, Erickson, Hans K., primary, Lambert, John M., primary, Chari, Ravi V.J., primary, and Widdison, Wayne C., primary

Published
2023
Full Text
View/download PDF

15. Supplementary Table from A New Triglycyl Peptide Linker for Antibody–Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells

Author

Singh, Rajeeva, primary, Setiady, Yulius Y., primary, Ponte, Jose, primary, Kovtun, Yelena V., primary, Lai, Katharine C., primary, Hong, E. Erica, primary, Fishkin, Nathan, primary, Dong, Ling, primary, Jones, Gregory E., primary, Coccia, Jennifer A., primary, Lanieri, Leanne, primary, Veale, Karen, primary, Costoplus, Juliet A., primary, Skaletskaya, Anna, primary, Gabriel, Rabih, primary, Salomon, Paulin, primary, Wu, Rui, primary, Qiu, Qifeng, primary, Erickson, Hans K., primary, Lambert, John M., primary, Chari, Ravi V.J., primary, and Widdison, Wayne C., primary

Published
2023
Full Text
View/download PDF

16. Supplementary Methods from A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity

Author

Miller, Michael L., primary, Fishkin, Nathan E., primary, Li, Wei, primary, Whiteman, Kathleen R., primary, Kovtun, Yelena, primary, Reid, Emily E., primary, Archer, Katie E., primary, Maloney, Erin K., primary, Audette, Charlene A., primary, Mayo, Michele F., primary, Wilhelm, Alan, primary, Modafferi, Holly A., primary, Singh, Rajeeva, primary, Pinkas, Jan, primary, Goldmacher, Victor, primary, Lambert, John M., primary, and Chari, Ravi V.J., primary

Published
2023
Full Text
View/download PDF

17. Data from A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity

Author

Miller, Michael L., primary, Fishkin, Nathan E., primary, Li, Wei, primary, Whiteman, Kathleen R., primary, Kovtun, Yelena, primary, Reid, Emily E., primary, Archer, Katie E., primary, Maloney, Erin K., primary, Audette, Charlene A., primary, Mayo, Michele F., primary, Wilhelm, Alan, primary, Modafferi, Holly A., primary, Singh, Rajeeva, primary, Pinkas, Jan, primary, Goldmacher, Victor, primary, Lambert, John M., primary, and Chari, Ravi V.J., primary

Published
2023
Full Text
View/download PDF

30. Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia

Author

Lapusan, Simona, Vidriales, Maria B., Thomas, Xavier, de Botton, Stephane, Vekhoff, Anne, Tang, Ruoping, Dumontet, Charles, Morariu-Zamfir, Rodica, Lambert, John M., Ozoux, Marie-Laure, Poncelet, Philippe, San Miguel, Jesus F., Legrand, Ollivier, DeAngelo, Daniel J., Giles, Francis J., and Marie, Jean-Pierre

Published
2012
Full Text
View/download PDF

39. Identification of three oligosaccharide binding sites in ricin

Author

Steeves, Rita M., Denton, Mary E., Barnard, Faith C., Henry, Andrew, and Lambert, John M.

Subjects
Binding sites (Biochemistry) -- Research, Ligand binding (Biochemistry) -- Research, Ricin -- Research, Biological sciences, Chemistry
Abstract

The location of the sites of covalent modification in blocked ricin were investigated. The amino acid residues of the ricin B chain covalently linked to reactive affinity ligands obtained from glycopeptides with triantennary N-linked oligosaccharides were determined by a method that exploited the disulfide moiety of the affinity ligand as a site for labeling with a purification tag. Results indicate that the two ligands of blocked ricin were covalently linked to the B chain at Lys 62 and Tyr 148.

Published
1999

46. A Case Study Comparing Heterogeneous Lysine- and Site-Specific Cysteine-Conjugated Maytansinoid Antibody-Drug Conjugates (ADCs) Illustrates the Benefits of Lysine Conjugation

Author

Yoder, Nicholas C., primary, Bai, Chen, additional, Tavares, Daniel, additional, Widdison, Wayne C., additional, Whiteman, Kathleen R., additional, Wilhelm, Alan, additional, Wilhelm, Sharon D., additional, McShea, Molly A., additional, Maloney, Erin K., additional, Ab, Olga, additional, Wang, Lintao, additional, Jin, Shan, additional, Erickson, Hans K., additional, Keating, Thomas A., additional, and Lambert, John M., additional

Published
2019
Full Text
View/download PDF

48. Elimination of neuroblastoma and small-cell lung cancer with an anti-neural cell adhesion molecule immunotoxin

Author

Roy, Denis C., Ouellet, Sophie, Le Houillier, Christiane, Ariniello, Pamela D., Perreault, Claude, and Lambert, John M.

Subjects
Neuroblastoma, Lung cancer, Small cell, Antibody-toxin conjugates -- Health aspects, Health
Abstract

Background: The development of immunotoxins has been hampered by difficulties, particularly in solid tumors, of finding appropriate target antigens and of linking sufficiently potent toxins. Purpose: We evaluated the tissue specificity of an immunotoxin, N901-blocked ricin (N901-bR), and assessed its potential for eliminating neural cell adhesion molecule (NCAM)-positive tumor cells in conditions appropriate for in vitro purging, prior to autologous stem cell transplantation, and its potential for myelosuppression. N901-bR consists of a monoclonal antibody (MAb), N901, directed against CD56, an antigen of the family of NCAMs, covalently linked to blocked ricin as the cytotoxic effector moiety. Methods: The tissue specificity of the N901 MAb and the N901-bR immunotoxin was tested against a wide array of human tumor tissues and normal human tissues by immunohistochemical staining. The cytotoxic activity of N901bR was tested against both small-cell lung cancer (SCLC) cells and neuroblastoma cells, either alone or among normal bone marrow mononuclear cells, and the efficacy of this treatment to specifically eliminate these cells was evaluated in a limiting dilution assay. In addition, normal bone marrow mononuclear cells were incubated with N901-bR, and the toxic effects of the immunotoxin on normal hematopoietic progenitors was evaluated. Results: N901 and N901-bR exhibited specificity for several neoplasms of neuroectodermal origin, including SCLC and neuroblastoma. Staining of normal tissues was essentially limited to various neuroendocrine cells, cardiac muscle cells, and cells in peripheral nerve tissue. We observed a time- and dose-dependent elimination of tumor cells in vitro, with three logs (i.e., >99.9%) of malignant cells being killed following only 5 hours of exposure to 10 nM N901-bR. Unconjugated N901 MAb specifically blocked the elimination of NCAM-positive cells by N901-bR, whereas neither an isotype-matched control MAb nor galactose (the ligand of native ricin) had any effect on the activity of the immunotoxin, confirming the specificity of its cytotoxic activity. Importantly, N901-bR used under optimal conditions for in vitro tumor cell depletion was not toxic to hematopoietic precursors. Conclusions: N901-bR has the properties required to target CD56, an antigen present not only on cells from a large number of cancers of neuroendocrine origin, but also on some important normal tissues. In addition, treatment with this immunotoxin results in the highly effective and specific elimination of neuroblastoma and SCLC cells and does not affect normal hematopoietic progenitors. Implications: N901-bR may have clinical utility for purging of neuroblastoma cells and SCLC cells before autologous stem cell transplantation. Further toxicology studies are warranted to assess the potential of N901-bR for in vivo administration. [J Natl Cancer Inst 1996;88:1136-45]

Published
1996

Catalog

Books, media, physical & digital resources
See catalog results